Tetra Bio-Pharma Publicizes Outcomes of Synthetic Intelligence Examine of ARDS-003 Mixed with Favipiravir

Tetra Bio-Pharma Publicizes Outcomes of Synthetic Intelligence Examine of ARDS-003 Mixed with Favipiravir

Dr. Man Chamberland, CEO and Chief Regulatory Officer at Tetra commented “We’re more than happy by these synthetic intelligence outcomes in addition to the current constructive outcomes from the PIONEER trial. This underscores our dedication with Cellvera to growing an revolutionary mixture drug candidate to fight viral ailments. We’re extra excited than ever about our […]

Continue Reading